Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG).

Full DD Report for EYEG

You must become a subscriber to view this report.


Recent News from (NASDAQ: EYEG)

EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye...
Source: GlobeNewswire
Date: May, 16 2018 16:30
EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
WALTHAM, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye...
Source: GlobeNewswire
Date: May, 11 2018 08:29
Daily Insider Ratings Round Up 4/20/18: PDVW, SMPL, CCUR, DEX, CIK, EYEG
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: April, 24 2018 22:15
Daily Insider Ratings Round Up 4/17/18: PDVW, LGCY, OPK, EYEG
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: April, 18 2018 19:16
EyeGate Announces Completion of $11.25 Million Public Offering
WALTHAM, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye,...
Source: GlobeNewswire
Date: April, 17 2018 16:30
Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data
A nalysis focus: Intercept Intercept Pharmaceuticals ( ICPT ) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis. ...
Source: SeekingAlpha
Date: April, 16 2018 08:00
EyeGate Pharma prices $11.25M equity offering; shares down 24% premarket
EyeGate Pharmaceuticals (NASDAQ: EYEG ) prices its public offering of ~35.2M shares of common stock at $0.32 per share. Each share will have an accompanying warrant to purchase one share of common at $0.32. Gross proceeds will be $11.25M. Closing date is April 17. More news on: EyeGate P...
Source: SeekingAlpha
Date: April, 13 2018 07:22
EyeGate Announces $11.25 Million Public Offering
WALTHAM, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the e...
Source: GlobeNewswire
Date: April, 13 2018 07:00
EyeGate Issued New Patent for Iontophoretic Contact Lens Technology
WALTHAM, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the e...
Source: GlobeNewswire
Date: April, 11 2018 08:30
Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback
A nalysis focus: Acadia Today we will discuss Acadia Pharmaceuticals (ACAD), which has fallen sharply on a CNN report that raised concerns about the Nuplazid’s safety. The CNN article notes that there were always safety concerns with the drug and that some committee mem...
Source: SeekingAlpha
Date: April, 10 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-160.5250.53480.5350.5241,811
2018-08-150.52730.52080.530.5276,482
2018-08-140.520.520070.5290.5115125,229
2018-08-130.5350.5230.540.51286,367
2018-08-100.520.51560.5350.5156139,162

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-162,72213,51220.1451Cover
2018-08-157,94730,15426.3547Cover
2018-08-1412,81545,72328.0275Cover
2018-08-13101,012118,28585.3971Short
2018-08-1050,73356,01590.5704Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EYEG.


About Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG)

Logo for Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG)

EyeGate is a clinical stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP , the company s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through EyeGate s proprietary innovative drug delivery system, the EyeGate II Delivery System. For more information, please visit www.EyeGatePharma.com.

 

Contact Information

 

 

Current Management

  • Stephen From / CEO, CFO
  • Michael Manzo / VP, Eng.
  • Paul Chaney / Chairman
  • Thomas Balland /
  • Mounia Chaoui /
  • Stephen From /
  • Morton Goldberg /
  • Thomas E. Hancock /
  • Bernard MalfroyCamine /
  • Praveen Tyle /

Current Share Structure

  • Market Cap: $26,093,547 - 05/16/2018
  • Authorized: 100,000,000 - 05/01/2018
  • Issue and Outstanding: 41,411,755 - 05/01/2018

 


Recent Filings from (NASDAQ: EYEG)

Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: May, 17 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 23 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 23 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 18 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Prospectus filed under Rule 424(b)(4)
Filing Type: 424B4Filing Source: edgar
Filing Date: April, 16 2018

 

 


Daily Technical Chart for (NASDAQ: EYEG)

Daily Technical Chart for (NASDAQ: EYEG)


Stay tuned for daily updates and more on (NASDAQ: EYEG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EYEG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EYEG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EYEG and does not buy, sell, or trade any shares of EYEG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/